Terazosin Hydrochloride
Product Images NDC 21695-812

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Terazosin Hydrochloride (NDC 21695-812). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (A00604ff 041d 4ad4 A3bb D0911bf0727e 01)

Chemical structure of Terazosin Hydrochloride showing its molecular formula C19H25N5O4·HCl with a detailed arrangement of rings, nitrogen, oxygen, and other atoms forming the compound.*

FDA Label Image

Figure 1 (A00604ff 041d 4ad4 A3bb D0911bf0727e 02)

Figure 1 from Study 1 shows two line graphs comparing Terazosin and placebo groups over three months. The left graph presents mean change in total symptom score from baseline, and the right graph shows mean increase in peak flow rate (mL/sec) from baseline, with error bars and sample sizes noted for both groups.*

FDA Label Image

Figure 2 (A00604ff 041d 4ad4 A3bb D0911bf0727e 03)

Line graph titled 'Mean Change in Total Symptom Score from Baseline Long-Term, Open-Label, Non-Placebo Controlled Study' for Terazosin Hydrochloride involving 494 subjects. The y-axis shows mean change from baseline (negative values indicate improvement), and the x-axis shows time in months from 0 to 30. Two lines with data points show symptom score changes over time, with statistically significant changes marked by asterisks compared to baseline.*

FDA Label Image

Figure 3 (A00604ff 041d 4ad4 A3bb D0911bf0727e 04)

A line graph titled "Mean Change in Peak Flow Rate from Baseline Long-Term, Open-Label, Non-Placebo Controlled Study (N=494)" showing mean change from baseline in milliliters per second over 30 months. The graph includes data points with significance markers indicating p ≤ 0.05 versus baseline, illustrating changes in peak flow rate with time.*

FDA Label Image

Terazosin HCl 2mg (A00604ff 041d 4ad4 A3bb D0911bf0727e 05)

Packaging label for Terazosin Hydrochloride 2mg capsules by Rebel Distributors Corp. The label shows product name, strength, dosage form, NDC 21695-812-90, lot number, expiration date, and barcodes. It includes instructions that the capsules have an ivory opaque cap and body with black print. The label also states that it is RX only, packaged by Physician Partner, Thousand Oaks, CA, and manufactured by Cadista Pharmaceuticals, Inc., Salisbury, MD, USA.*

FDA Label Image

Terazosin HCl 5mg (A00604ff 041d 4ad4 A3bb D0911bf0727e 06)

Terazosin Hydrochloride 5mg capsules label by Physician Partner. This label indicates a 30-capsule package with each capsule containing Terazosin Hydrochloride equivalent to 5mg Terazosin. The capsules are described as bright orange in color with specific print markings. Packaged by Physician Partner in Thousand Oaks, CA, and manufactured by Cadista Pharmaceuticals, Inc., Salisbury, MD.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.